Navigation Links
Abbott's Investigational Treatment ABT-874 Shows Positive Results,in Phase II Psoriasis Study

earance (results were, respectively, 17 percent, 53 percent, 63 percent, 77 percent, 53 percent, vs. 0 percent of those receiving placebo; p<0.001 for all groups except the single-dose group, 200mg at week 0).

The most common adverse events observed were injection site reactions, nasopharyngitis (inflammation of the nose and pharynx), upper respiratory infections and headache.

"We're very excited about these promising Phase II results," said Eugene Sun, M.D., vice president, Global Pharmaceutical Clinical Development at Abbott. "In all but one of the dosing groups in this study, at least 90 percent of patients showed significant improvement, and many experienced almost complete clearance. We look forward to studying ABT-874 further."

Abbott's Commitment to Immunology

Abbott is focused on the discovery and development of innovative treatments for immunologic diseases. The Abbott Bioresearch Center, founded in 1989 in Worcester, Mass., United States, is a world-class discovery and basic research facility supporting research and development of biologic treatments. Abbott Biotechnology Limited, which opened earlier this year in Barceloneta, Puerto Rico, United States, is the main production facility for Abbott's anti-TNF treatment and one of the world's largest centers for production of monoclonal antibodies.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 65,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.

CONTACT: U.S. Media, Liz Shea, +1-847-935-2211, or International Media,Tracy Sorrentino, +1-847-937-8712, or Financial, John Thomas,+1-847-938-26
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
2. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
3. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
6. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
7. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
8. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
9. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
10. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
11. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting

Post Your Comments:
(Date:11/6/2009)...- Trius Therapeutics, Inc. announced today that it...th the U.S. Securities and Exchange Commission (SE...of shares of its common stock. All shares of the c...ered by the Company. ,, Credit Suisse Securitie..., Piper Jaffray & Co. is acting as co-lead man...
(Date:11/6/2009)...re-FirstCall/ -- Roper Industries, Inc. (NYSE: R...ive agreement to acquire Verathon, Inc., a leading...athon Board of Directors has approved the transact...tory approvals and closing conditions, including s...ng to be completed in early December. ,, Headq...
(Date:11/6/2009)...ire-FirstCall/ -- Derma Sciences, Inc. (OTC Bu...care products, announced plans to release its thir...vember 16, 2009. The Company will hold a conferenc...00 am EST. Interested parties should call (866) 78...), with passcode 81416481 to access the call. You ...
Breaking Medicine Technology:Roper Industries Announces Two Acquisitions to Enhance Growth in Medical and Toll & Traffic Businesses 2Roper Industries Announces Two Acquisitions to Enhance Growth in Medical and Toll & Traffic Businesses 3Derma Sciences Announces Date of Its Third Quarter 2009 Earnings Release and Conference Call 2Genes may explain why children who live without dads have earlier sex 9923 1Genes may explain why children who live without dads have earlier sex 9923 2The Pancreatic Cancer Action Network Is Saddened by the Death of Actor Patrick Swayze 57133 1The Pancreatic Cancer Action Network Is Saddened by the Death of Actor Patrick Swayze 57133 2Molecules on a string and why size isnt the only thing that matters for data storage 14038 1Molecules on a string and why size isnt the only thing that matters for data storage 14038 2
...cs, Inc., a,privately-held biopharmaceutical compa...n of proprietary compounds to treat gastrointestin...completed the patient enrollment,of its Phase 3 st...ouble-blind, placebo controlled study, FHAST1 (Fis...etermine the efficacy and safety of oral,AST-120 i...
...l Meeting of the American Neurological ..., Oct. 8 UCB, Inc. presented results from two,Pha... trial of rotigotine,transdermal system for the tr...me (RLS). These rotigotine data showed significant... 8 points over placebo using the,International Res...
Other Medicine Technology:Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohn's Disease 2Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohn's Disease 3Rotigotine Transdermal System Shows Significant Symptom Reduction and Tolerability in Patients with Restless Legs Syndrome 2Rotigotine Transdermal System Shows Significant Symptom Reduction and Tolerability in Patients with Restless Legs Syndrome 3Rotigotine Transdermal System Shows Significant Symptom Reduction and Tolerability in Patients with Restless Legs Syndrome 4Rotigotine Transdermal System Shows Significant Symptom Reduction and Tolerability in Patients with Restless Legs Syndrome 5
(Date:11/8/2009)... , "One victory does not mean the battle is ... Nov. 7 In a vote of 24...r-Lipinski-Smith Amendment to prohibit abortion ma...floor. ,, Americans United for Life Action Pres...ge of this amendment is a victory for the pro-life...
(Date:11/8/2009)... , WASHINGTON, Nov. 7 /PRNewswire-USNewswire/...fordable Health Care for America Act, which will m...d insurance companies accountable and increase acc...gh a public option. ,, "Teddy Roosevelt, FDR an...ram Director Alan Charney. "Today,s vote ranks amo...
(Date:11/8/2009)... , Calls for Swift Passage of H.R. 3961 to S...v. 7 Statement Attribut...n Medical Association. ,, (Logo: http://www.n... "The AMA hails the passage of the House health re...em for patients and physicians and calls for swift...
(Date:11/8/2009)... , AARP Praises House Passage of Health Care...rengthen Medicare, improve coverage for all Americ... -- Today, the United States House of Representati...are reform legislation that would strengthen Medic...e companies that prices millions of Americans out ...
(Date:11/8/2009)... , AARP Praises House Passage of Health Care...rengthen Medicare, improve coverage for all Americ...e/ -- SUMMARY: Tonight the United States House o...rm legislation that would strengthen Medicare for ...ies that prices millions of Americans out of affor...
Breaking Medicine News(10 mins):Health News:Americans United for Life Action Comments on Passage of Pro-Life Amendment: Bipartisan Pro-life Majority Reflects the Will of the American People 2Health News:AMA Hails House Passage of Health Reform Bill (H.R. 3962) 2Health News:AARP Illinois Key Vote News Alert 2Health News:AARP Illinois Key Vote News Alert 3Health News:AARP Maryland Key Vote News Alert 2Health News:AARP Maryland Key Vote News Alert 3
...ano’s bestseller ‘French Women Don’t Get Fat’ may ...es, 5.9 million of France's 63.4 million// people ...igures have got the French government scratching t... down hard on junk food advertisements. Such adver...
...wance of ?9,000 per year will be given to dentists...Scotland//. This was announced by the Scottish Exe...re will enjoy this special allowance. This scheme ...area. Craigmiller is the poorest area when income ...
... of bread available in the supermarket were found ...s the Consensus Action// on Salt and Health (Cash)...f them contained more salt than the Food Standards...as found that some brands were so salty that nine ...
...s of China and France signed a landmark cooperativ...aditional// Chinese medicine (TCM) expected by pra...ancer. The two countries will cooperate in a...the document signed by Chinese Health Minister Gao...
...a's Fujian province was on high alert after it con...Thursday//. Zhang Changpin, vice governor of F... to prevent an outbreak of the epidemic. He asked ... in Jian'ou city, developed symptoms of fever, cou...
...sts say a simple test can identify men at high ris... biopsy finds no signs of it//. The key, researche...of a man's prostate with his levels of a cancer-re...ancers than men with lower scores in an Oregon stu...
Other Medicine News:Health News:Too Much of Salt in Bread.. 2Health News:Scientists Tout New Prostate Cancer Test 2
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
Medicine Products: